

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

*For the month of July 2013*

---

**BioLineRx Ltd.**

(Translation of Registrant's name into English)

---

**P.O. Box 45158  
19 Hartum Street  
Jerusalem 9777518, Israel**

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F**  **Form 40-F**

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

**Yes**  **No**

---

Further to its Current Report on Form 6-K dated June 5, 2013 the Registrant announces the following results of its Extraordinary General Meeting of Shareholders which was held on July 11, 2013 at 11:00 a.m. (Israel time):

In respect of Proposal 1 – The required majority of shareholders who participated in the meeting and voted either in person or by proxy, voted in favor of the re-election of Ms. Nurit Benjamini to serve on the Board of Directors of the Company for an additional three-year term as external director, commencing as of July 6, 2013, and of the grant of options to Ms. Benjamini.

In respect of Proposal 2 – The required majority of shareholders who participated in the meeting and voted either in person or by proxy, voted in favor of the re-election of Dr. Avraham Molcho to serve on the Board of Directors of the Company for an additional three-year term as external director, commencing as of July 6, 2013, and of the grant of options to Dr. Molcho.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioLineRx Ltd.**

By: /s/ Philip Serlin  
Philip Serlin  
Chief Financial and Operating  
Officer

Dated: July 11, 2013

---